Update in indemnification process relating to US patent dispute

Regulatory press release
May 07 2023

Update in indemnification process relating to US patent dispute

Following the settlement in the US patent dispute on 4 April, Vimian has initiated the process to retrieve compensation from the Sellers of Vimian’s subsidiary Veterinary Orthopedic Implants LLC (“VOI”) as per the indemnification in the purchase agreement from the acquisition of VOI. Vimian has received information that a complaint was filed against Vimian and three affiliates of Vimian in the Superior Court of the State of Delaware. Three of the main Sellers state in the complaint that they disagree with Vimian’s indemnification claim.

Vimian’s view remains unchanged that it, through the purchase agreement for the acquisition of VOI, has contractual indemnification protection for the amount of the settlement and all legal costs to date.

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 90 markets, employs close to 900 people and has annual turnover of approximately EUR 280 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company’s Certified Adviser.